The four dengue virus serotypes (DENV1-4) are mosquito-borne flaviviruses that infect ~390 million people annually; up to 100 million infections are symptomatic, and 500,000 cases progress to severe disease. Exposure to a heterologous DENV serotype, the specific infecting DENV strains, and the interval of time between infections, as well as age, ethnicity, genetic polymorphisms, and co-morbidities of the host, are all risk factors for severe dengue. In contrast, neutralizing antibodies (NAbs) are thought to provide long-lived protection against symptomatic infection and severe dengue. The objective of dengue vaccines is to provide balanced protection against all DENV serotypes simultaneously. However, the association between homotypic and heterotypic NAb titers and protection against symptomatic infection remains poorly understood.
INTRODUCTION
Dengue virus (DENV) is a mosquito-borne flavivirus that infects up to 390 million individuals each year (1) . While most infections are inapparent, ~25% of infections cause acute febrile illness, which progresses to severe disease in half a million individuals annually (2) . DENV consists of four evolutionarily distinct, antigenically related DENV serotypes, DENV1-4, and neutralizing antibodies (NAbs) against the four serotypes are considered a critical component of the protective immune response (3, 4) . Primary (1°) DENV infection induces a NAb response that is described as increasingly type-specific over time, providing long-term protection against the 1° infecting serotype but only transient protection against other DENV serotypes (5, 6).
Cross-serotype protection against symptomatic infection is observed for up to two years after 1° infection, after which point individuals are at increased risk of symptomatic infection and severe dengue upon subsequent heterologous infection (7-10). Over time, cross-serotype-reactive antibodies are thought to decay to sub-neutralizing levels, binding but not neutralizing DENV and contributing to enhanced replication during heterologous infection by facilitating virus entry into target cells expressing Fc receptors (11). However, following subsequent infection with a different serotype, the NAb response becomes broadly neutralizing, and is thought to reduce incidence of severe disease (12).
There has been limited success in establishing the relationship between the level of pre-infection NAb titers to DENV and risk of disease upon subsequent DENV infection in endemic settings.
In recent vaccine trials, symptomatic disease was observed in individuals with relatively high NAb titers, raising concerns that the current immunologic assays do not measure the NAbs critical for protection (13) . In studies of infants, who receive IgG antibodies by trans-placental transfer from DENV-immune mothers, infants with higher NAb titers at birth generally, although not always, experienced symptomatic disease later than those with lower titers (14-16). Recent studies in children and adults have made important advances in demonstrating an association between the quantity of cross-reactive pre-infection NAb titers and reduced risk of symptomatic secondary (2°) infection, defined as >2 infections, but have not been conclusive: the association did not hold for all DENV serotypes (15, 17), exposure could not be proven for DENV-negative individuals (18), or the magnitude of pre-infection NAb titers was not directly studied (12, 19).
Thus, there is an urgent need to definitively establish whether NAb titers correlate with protection in endemic settings. Here, we estimated the relationship between pre-infection NAb titers and probability of symptomatic infection and characterized determinants of long-term ! 4! protection in children with multiple DENV infections in a pediatric dengue cohort study in Nicaragua.
RESULTS
Selection of the repeat infection sample set. The Nicaraguan Pediatric Dengue Cohort Study (PDCS, 2004-present ) is a community-based study with "enhanced" passive surveillance with an average active cohort of ~3,500 children (7,547 to date) aged 2-14 years in Managua. Healthy annual blood samples are collected from all participants each year (in July/August prior to 2011
and March/April since 2011). Symptomatic infections are confirmed in children who present to the study Health Center with suspected dengue or undifferentiated febrile illnesses by RT-PCR and/or virus isolation in acute samples, and/or serological assays in paired acute and convalescent samples (20) . Inapparent infections are identified using Inhibition ELISA (IE) on paired healthy annual samples processed side-by-side each year, defined as seroconversion (1° infections) or a >4-fold increase in anti-DENV antibody titer (2° infections) (21). By IE, we capture ~80% of symptomatic infections, as reported previously (21). In total, 1,114 children were DENV-naïve at enrollment and experienced >1 infection. From this group, we assembled the "repeat infection sample set" by randomly selecting 62/224 with 2 infections and 32/54 with 3 infections as identified by either IE or symptomatic infection; 18/834 with 1 infection were also selected for comparison (n=112 total) (9). Children in the sample set were an average of 6.19 years old at the time of their first DENV infection, and 45% were female (see SI Appendix, Table S1 ).
To reconstruct the immunological history of each child in the repeat infection sample set, NAb titers to the four DENV serotypes were measured in annual samples from all available years. NAb titers were measured by endpoint titration and calculated as 50% neutralization (NT 50 ) in a flow cytometry-based assay using human Raji-DC-SIGNR cells with reporter virus particles (RVPs) representing the four DENV serotypes (9, 22). Titrations were only accepted once they met stringent quality control standards (see Methods) (9).
Inapparent infections were classified using the same criteria as previously reported (9): a >4-fold increase in NAb titer between annual samples to a DENV serotype other than a previous infecting DENV serotype or a serotype that later caused a symptomatic infection (hereafter called the standard infection criteria). Based on analyses of reproducibility of positive control ! 5! titrations, we expect identical serum samples titrated against all four DENV types at two timepoints to exhibit a >4-fold increase in titer for at least one of the four measured titers, and thus incorrectly be coded as an infection, in only 0.9-1.0% of comparisons (see SI Appendix, Fig.   S1 ). Compared with inapparent infections identified by applying standard infection criteria to the NAb titers, inapparent infections identified by IE had a specificity 95% and a sensitivity of 64%.
With standard infection criteria, we identified 22 symptomatic 1°, 71 inapparent 1°, 38 symptomatic 2°, and 87 inapparent 2° DENV infections. Based on NAb responses, the children were grouped into the following subsets: subset 1 entered the study DENV-naïve and had >2 infections (n=69); subset 2 entered the study DENV-immune and >1 infection (n=19); and subset 3 entered the study DENV-naïve and had only 1 infection (n=24) (see SI Appendix, Table S2 ).
We also identified the infecting serotype as described in Methods. The serotype identified by RT-PCR corresponded to the greatest change in NAb titers in 94% of symptomatic 2° infections,! and!41% exhibited original antigenic sin, defined as a post-infection NAb titer higher to the 1° than to the 2° infecting serotype. For inapparent 2° infections, we identified the infecting serotype by considering the magnitude of the change in NAb titer as well as the epidemiology of DENV in the year of infection, as others have done (10), based on DENV infection data for the full PDCS (21). With these criteria, 76% of infections had the largest change in NAb titer to what was identified as the 2° infecting serotype, and 60% exhibited original antigenic sin.
Pre-infection neutralizing antibody titer predicts infection outcome. We first tested whether higher levels of cross-reactive NAb titers reduced the probability of symptomatic infection by estimating the relationship between pre-infection NAb titers measured in the annual sample before the 2° infection and symptomatic versus inapparent 2° DENV infections for subset 1, using single and multiple logistic regression. Pre-infection NAb titers were estimated as the median of NAb titers to the four serotypes, and covariates included age at 2° infection, number of years between 1° and 2° infection, or "epidemic force", a metric based on the annual ratio of symptomatic to inapparent (S:I) infections in the full PDCS (See Methods and SI Appendix, Fig.   S2 ).
In all multiple logistic regression models, children with a higher median pre-infection NAb titer were significantly less likely to experience symptomatic 2° infections (Fig. 1A , Table 1; see SI   Appendix, Tables S3, S4 ). When covariates in all models were set to the average value observed ! 6! in the sample, the probability of symptomatic infection decreased with higher levels of preinfection median NAb titer (Fig. 1B) . Based on the model "median NAb titer + epidemic force", individuals with a titer of 1:260 have a 10% probability of symptomatic infection in an average year. We tested the predictive ability of the model "median NAb titer + epidemic force" with cross-validation (see Methods).! Overall, the predicted probabilities corresponded well to the observed proportions of symptomatic DENV infections for each estimated probability group, similar to model parameters estimated with all children in subset 1 (see SI Appendix, Table S5 ).
We expanded our analyses of protection to also include subset 2 (DENV-immune upon study enrollment) and found that the protective effect of median pre-infection NAb titer remained significant (see SI Appendix, Table S6 ). In contrast, the pre-infection NAb titer to the 1° infecting serotype was not significantly associated with infection outcome, suggesting that the heterotypic NAbs were providing protection (Table 1; see SI Appendix, Tables S3-S4, S6) .
Alternative criteria for identifying inapparent DENV infections do not change the relationship between median pre-infection NAb titer and infection outcome. We conducted sensitivity analyses to determine whether the protective effect of median pre-infection NAb titer was robust to the criteria used to identify inapparent infections. Using "relaxed" infection criteria, defined as any >4-fold increase in NAb titer, thus allowing for re-infection with previous infecting serotypes, those in subset 1 with a higher median pre-infection NAb titer were at reduced risk of symptomatic disease (Table 1 ; see SI Appendix, Tables S2-S4). The relationship remained when also analyzing subsets 2 and 3 with the "relaxed" infection criteria (see SI Appendix, Table S6 ). We then applied more stringent criteria for inapparent infections, which consisted of the standard criteria as well as a median NAb titer increase of >1-fold. Although this reduced the number of inapparent infections, the effect of median pre-infection NAb titer on infection outcome remained (Table 1 ; see SI Appendix, Tables S3-S4, S6). We concluded that potential misclassification of inapparent infections would not substantively alter the measured relationship between NAb titer and protection.
Pre-infection neutralizing antibody titer to the 2° infecting serotype predicts infection outcome. We next tested whether the pre-infection NAb titer to the 2° infecting serotype was predictive of infection outcome. We found that, controlling for epidemic force or years between 1° and 2° infections, the NAb titer to the 2° infecting serotype was also associated with reduced likelihood of symptomatic infection (Table 1; 
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The effect size for the model "NAb titer to 2° serotype + epidemic force" remained similar when relaxed and stringent infection criteria were used (Table 1 ; see SI Appendix, S3-S4, S6), and also performed well in cross-validation analyses (Table S5) .
Epidemic force is the strongest independent predictor of symptomatic infection. We found that infection during years with a strong epidemic force, at older age, and with more time between 1° and 2° infection were all significantly associated with a higher probability of symptomatic 2° infection (Table 1) . However, the logistic model with "NAb titer + epidemic force" was more parsimonious (Akaike Information Criterion, AIC=102.2) than those with either age (AIC=117.0) or years between infections (AIC=116.5), and only epidemic force remained a significant independent predictor of symptomatic disease when controlling for age and years between 1° and 2° infections in the same regression model (See Methods and SI Appendix, Fig. S2 ).
When each model covariate was set to the value observed in 2009-2010, the effect of NAb titer on the probability of symptomatic infection was more striking (Fig. 1C) than that observed for average covariate values (Fig. 1B) .
Primary infection outcome modifies 2° infection outcome. We also tested whether the infecting DENV serotype and clinical outcome of the 1° infection modified the probability of symptomatic 2° infection in the model, "NAb titer + epidemic force". Children with symptomatic 1° infections were less likely to have symptomatic 2° infections independent of NAb titer (median or 2° serotype), suggesting that symptomatic 1° infection may modify subsequent disease risk in a way not fully measured by NAb titers. In contrast, we did not observe a significant relationship between either the 1° serotype or the 2° serotype and symptomatic 2° infection (see SI Appendix, Table S8 ).
Higher titers immediately after 1° infection delay the occurrence of symptomatic infection.
In studies of symptomatic dengue in infants of DENV-immune mothers, infants with later symptomatic infections have higher NAb titers at birth than those infected earlier (14-16),
suggesting that infants exposed after maternal antibodies had decayed to low levels were at ! 8! greater risk. We tested this hypothesis for subset 1 to determine whether children with higher NAb titers to the 2° infecting serotype immediately after 1° infection were protected for a longer period of time against symptomatic infection. We found that every two-fold higher NAb titer to the 2° serotype, as measured immediately after 1° infection, provided a six-month delay to symptomatic infection ( Fig. 2A) . We hypothesized that NAb titers would decay to low levels in all individuals in the year prior to their symptomatic 2° infections. However, we did not observe a significant difference in NAb titers to the 2° infecting serotype from immediately after 1°
infection to the year before 2° symptomatic infection (paired t-test, 1.23-fold increase, p=0.21) and children with later 2° infections, both symptomatic and inapparent, had more >4-fold increases in NAb titers between their 1° and 2° infections than those with earlier 2° infections (p<0.001, linear regression). Yet overall, those with 2° inapparent infections still consistently had higher pre-infection NAb titers than those with 2° symptomatic infections ( 
Neutralizing antibody titers increase in magnitude and breadth following 1° infection. In the absence of re-infection with DENV, post-1° infection NAb responses are expected to decay
and become increasingly type-specific over time (5) . We measured the magnitude and breadth of NAb titer trajectories following 1° infection and before the subsequent exposure to DENV (as identified with standard criteria) for subset 1 (>2 infections) and subset 3 (1 infection) (see Methods). In both subsets 1 and 3, we observed that the magnitude of NAb titers between 1° and subsequent infection increased modestly, but significantly ( Fig. 3 ; see SI Appendix, Table S9 ). A similar phenomenon was seen for the breadth of the NAb response: those in subset 1 became slightly more cross-serotype neutralizing over time, while subset 3 had stable NAb responses. In subset 1, we also measured the trajectories of NAb titers between 2° infections defined with standard criteria. NAb titers modestly declined in magnitude, but had stable cross-serotype neutralization over time ( Fig. 3 ; see SI Appendix, Table S9 ).
DISCUSSION
We have found that pre-infection NAb titers reduce the risk of symptomatic DENV infection in a longitudinal dengue cohort. We observed that a higher median pre-infection NAb titer or NAb titer to the 2° infecting serotype, but not the NAb titer to the 1° serotype, was significantly associated with reduced probability of 2° symptomatic DENV infection, indicating that cross-
reactive NAbs determine protection, as others have proposed (7, 8, 12, 17, 19) . The protective effect of pre-infection NAb titers remained when the criteria for inapparent infections were relaxed or made more stringent, and the models performed well in cross-validation experiments, reinforcing the strength of this observation. We also found that higher NAb titers to the 2° infecting type immediately after 1° infection delayed symptomatic 2° infections, but that this effect could not be attributed primarily to antibody decay, as NAb titers increased modestly in magnitude and remained serotype cross-reactive in the years between 1° and 2° infection.
Collectively, our findings establish that higher levels of cross-reactive pre-infection NAb titers correlate with reduced probability of symptomatic DENV infection, and that NAb titers do not become increasingly type-specific over time in endemic settings.
Our findings advance those of previous studies to establish the relationship between the quantity of NAbs and protection against DENV in an endemic setting. Previous longitudinal cohort studies in Thailand found that pre-infection NAb titers reduce the risk of severe disease (17), while studies in Sri Lanka and Peru found that the number of DENV serotypes that were detectably neutralized reduced the risk of symptomatic compared with inapparent 2° DENV infection (12, 19). A recent index-cluster study in Thailand found that individuals with symptomatic infections had lower pre-infection NAb titers than a comparable group of individuals likely, but not definitely, exposed to DENV but who did not become ill (18).
However, due to study limitations, these findings collectively do not provide definitive proof of the relationship between NAb titers and protection: the protective effect was not consistently observed against all DENV serotypes (17), the DENV-negative individuals may not have been exposed to DENV (18), and the magnitude of NAb titers was not directly analyzed (12, 19).
Beyond dengue cohort studies, there remains concern that NAb titers measured with non-human cell substrates are not as biologically relevant (13). Our study fills a critical gap in the literature, establishing that higher levels of pre-infection NAb titers reduce the risk of symptomatic compared with inapparent DENV infection in a longitudinal cohort of children infected repeatedly over multiple years, as measured using a statistically robust neutralization assay on a human cell substrate. Future studies that measure other functional properties of NAbs will be important for establishing the mechanism of such neutralization.
We observed that age, interval between 1° and 2° infections, and epidemic force in the year of 2° infection were independent predictors of 2° infection outcome. However, in models including ! 10! epidemic force and either age or years between 1° and 2° infections, only epidemic force remained significant, suggesting that it was the major independent predictor of infection outcome besides pre-infection NAb titer. Previous studies have found that the time between 1° and 2°
infections is a strong predictor of infection outcome (7-9). However, in other studies, age and years between infections were used as an indirect measure of NAb titers (older children are more likely to have higher NAb titers, and more years between infection may correlate with antibody decay), whereas we have estimated the effect of NAb titer on infection outcome directly.
Interestingly, Anderson et al. (7) observed an effect of time on infection outcome independent of antibody response, suggesting that perhaps an effect of epidemic force has been observed in other settings.
Epidemic force is likely a function of whether a major epidemic occurred recently, the virulence/transmissibility of the infecting serotype and strain, and the antigenic properties of the strain in relation to population immunity and the serotypes and strains that circulated previously.
That there are major fluctuations in the annual S:I ratio is well established and has been observed by all longitudinal cohort studies conducted to date (26). The DENV serotypes are also observed to have intrinsic differences: DENV1 and DENV3 cause more symptomatic/severe primary infections than DENV2 and DENV4, DENV2 causes the most symptomatic/severe secondary infections, DENV3 is associated with the largest epidemics, and DENV4 infections tend to be mild or subclinical (23, 24, 27, 28). Within serotypes, there may also be differences in epidemic potential of genotypes or clades, due to either their antigenic properties in relation to population immunity or their intrinsic fitness differences (28-31). Of note, the years with the strongest epidemic force described here coincided with the re-introduction of DENV3 into Nicaragua, similar to what occurred in Iquitos, Peru, in 2001-2002, where DENV3 was introduced into a population previously only infected with DENV1 and DENV2, leading to an initial high S:I infection ratio (24). Our findings suggest that the NAb titer that distinguishes those with a high probability of symptomatic compared with inapparent infection may depend on the annual S:I ratio and thus may vary in relation to the risk of disease given DENV infection from year to year (29-31). This raises the possibility that there may not be a single NAb titer that correlates with protection from symptomatic infection, even for each DENV serotype, and that it may differ from epidemic to epidemic.
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We also found that the 1° infection outcome independently predicted subsequent symptomatic DENV infection. We did not observe any significant differences in 2° infection outcome by 1° or 2° infecting serotype, but our study was not powered to test the specific relationship between serotypes. The sequence of infecting serotypes has been shown to be important in other cohorts and settings (29, 30). In future studies using higher resolution antigenic and epidemiological data, it may be possible to identify the specific antigenic relationship between the 1° and 2°
infecting DENV isolates, particularly if using Nicaraguan strains, rather than prototype isolates, for the neutralization assays (32).
Our findings also provide insight into the maintenance of protective NAbs in endemic settings.
We found that children with higher NAb titers immediately after 1° infection were protected for longer against symptomatic infection than those with lower titers, but this effect does not appear to be due to antibody decay, as NAb titers modestly increased between the year after 1° infection and the year before 2° infection. Our study was conducted in an endemic setting, whereas previous studies of neutralizing responses in individuals long after 1° infection were conducted in non-endemic areas (5). However, in a comparable hospital-based study following pediatric dengue cases in Nicaragua, NAb titers declined in magnitude between 2 weeks and 6 months post-infection, but increased between 6 to 18 months post-infection for a subset of individuals, suggesting subsequent DENV-exposure (33). These observations raise the possibility that many children in the Nicaraguan cohort were exposed to DENV more often than is measured using standard infection criteria.
The frequency of boosts in NAb titer observed in the repeat infection sample set suggest that Overall, we demonstrate that high NAb titers are associated with reduced probability of symptomatic infection in DENV-endemic areas. Further, our data suggest that regular DENV reexposure, including to homologous DENV types, may help maintain these high levels of NAb titers over time.
MATERIALS AND METHODS
Neutralization titrations. NAb titers were measured as 50% neutralization (relative to no antibody control) in a flow cytometry-based assay using human Raji-DC-SIGNR cells with reporter virus particles (RVPs) representing the four DENV serotypes: DENV1, Western Pacific ! 13! 74; DENV2, S16803; DENV3, CH53489; DENV4, TVP360 (9, 22). Where possible, all annual samples for each child were titrated side-by-side. The raw antibody titration data were fitted with a two-parameter (slope and intercept) sigmoidal dose-response curve to estimate the NAb titer (NT 50 ). The RVP concentrations were tested to ensure they abided by the law of mass action. Quality control standards were implemented for the sigmoidal dose-response regression fit, including an absolute sum of squares <0.2 and the coefficient of determination (R 2 ) >0.9 (9).
Identifying the infecting serotype. If an individual had a >4-fold increase to only one serotype, that serotype was identified as the infecting serotype. However, in Nicaragua, generally one DENV serotype causes the majority of infections in any given year. Thus, if the individual also had a >1.5-fold increase in NAb titer to a serotype with higher incidence in that year (based on incidence data for the full PDCS), the higher-incidence serotype was identified as the infecting serotype. We conducted sensitivity analyses and found that the effect sizes and p-values estimated with different fold-increases (>1-fold, >2-fold, or >4-fold) were similar to those estimated with >1.5-fold increase. As a sensitivity analysis, we also defined epidemic force using only the S:I ratio for 1° infections in the whole PDCS and obtained similar results (see SI Appendix, Table S4 ).
Magnitude and breadth. Magnitude was estimated as the mean of NAb titers to all four DENV
serotypes for each individual at each time point. Breadth was estimated by identifying the best and second-best neutralized DENV serotypes in the year immediately after 1° infection, and measuring the ratio of the two NAb titers for each individual at each time point.
Statistical analyses. All statistical analyses were conducted using R version 3.1.3. We used logistic regression to test the association between median pre-infection NAb titers or the NAb titer to the 2° serotype and 2° infection outcome, controlling for age at 2° infection, years between 1° and 2° infection, or epidemic force. Effects were estimated as the average marginal effect (AME, which allows comparison between models (37)), odds ratios (OR), or the ! 14! probability of symptomatic infection (the OR/(1+OR)). We conducted cross validation of the model "NAb titer + epidemic force" by estimating model parameters with data from a randomly selected sample of 90% of children in subset 1 and used the resulting model to predict the probability of symptomatic infection for the excluded 10%, repeating this process 10,000 times, using different random subsets. We used the AIC to compare logistic regression models with pre-infection NAb titer and age, years between 1° and 2° infections, or epidemic force. We built logistic regression models with multiple covariates to test the importance of each in relation to 2° infection outcome. We estimated the relationship between NAb titers and years until 2° infection 
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We are also extremely grateful to the study participants and their families. The odds ratio (OR) is change in the odds of symptomatic to inapparent DENV infection for each two-fold increase in NAb titer or one unit increase in the covariate value. 2 The average marginal effect (AME) is the average effect of NAb titer or the covariate on the probability of symptomatic infection. 3 Infection criteria: standard (std.), relaxed (rel.), stringent (str.). 1 Subset 1: children who entered the study DENV-naïve and had >2 infections (n=69).
2 Subset 2: children who entered the study DENV-immune and had >1 infection (n=19).
3 Subset 3: children who entered the study DENV-naïve and had only one infection (n=24). 4 If immune at study enrollment (subset 2), the year of entry into the PDCS is used instead of the year of 1° infection.
! 28! Table S2 . Number of 2° infections identified using different criteria for inapparent infections.
1 Symptomatic infections are denoted S, inapparent infections, I.
2 Standard infection criteria: a >4-fold increase to a DENV serotype an individual has not been infected with previously and to which they do not have a later symptomatic DENV infection. 3 Relaxed infection criteria: any >4-fold increase in NAb titer. 4 Stringent infection criteria: a >4-fold increase to a DENV serotype an individual has not been infected with previously and to which they do not have a later symptomatic DENV infection, plus an overall increase in median NAb titers. Table S3 . Relationship between pre-infection NAb titers and likelihood of symptomatic 2° infection (subset 1). 1 The odds ratio (OR) is change in the odds of symptomatic to inapparent infection for each 2-fold increase in NAb titer. 2 The average marginal effect (AME) is the average effect of NAb titer on the probability of symptomatic infection.
!
Single logistic regression (subset 1) Table S4 . Relationship between pre-infection NAb titers and likelihood of symptomatic 2° infection (subset 1), with epidemic force estimated from 1° infection S:I ratio in the whole PDCS. 1 The odds ratio (OR) is change in the odds of symptomatic to inapparent DENV infection for each 2-fold increase in NAb titer or one unit increase in the epidemic force. 2 The average marginal effect (AME) is the average effect of NAb titer or epidemic force on the probability of symptomatic infection. 3 Epidemic force is defined here by the 1° infection S:I ratio in the whole PDCS. 2 The odds ratio (OR) is change in the odds of symptomatic to inapparent DENV infection for each 2-fold increase in NAb titer or one unit increase in the epidemic force. 3 The average marginal effect (AME) is the average effect of NAb titer or epidemic force on the probability of symptomatic infection. 4 The estimate of epidemic force is only shown for the model including pre-infection NAb titer with standard infection criteria, but was included in all models. 1 The odds ratio (OR) is change in the odds of symptomatic to inapparent DENV infection for each 2-fold increase in NAb titer or one unit increase in the covariate value. 2 The average marginal effect (AME) is the average effect of NAb titer or the covariate on the probability of symptomatic infection.
! 34! 1 The odds ratio (OR) is change in the odds of symptomatic to inapparent DENV infection for each 2-fold increase in NAb titer or one unit increase in the covariate value. 2 The average marginal effect (AME) is the average effect of NAb titer or the covariate on the probability of symptomatic infection. 3 Effect of 1° DENV2 infection relative to 1° DENV1 infection (OR=1). There were not enough 1° DENV3 or DENV4 infections in the sample set for analysis. 
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